BSPK: Bespoke Extracts, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.45
Enterprise Value ($M) 2.88
Book Value ($M) -2.09
Book Value / Share -0.19
Price / Book -0.69
NCAV ($M) -2.29
NCAV / Share -0.20
Price / NCAV -0.63

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -2.93
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.12
Current Ratio 0.15

Balance Sheet (mrq) ($M)
Current Assets 0.17
Assets 0.36
Liabilities 2.45
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 1.12
Operating Income -0.99
Net Income -1.04
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.29
Cash from Investing 0.00
Cash from Financing 0.34

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-04-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 ☐ TRANSITION REPORT PURSUAN
2024-10-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO
2024-07-02 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)

Similar Companies
BPTH – Bio-Path Holdings, Inc. BQST – BioQuest Corp.
BSEM – BioStem Technologies, Inc. BSPM – Biostar Pharmaceuticals, Inc.
BTAX – Biostax Corp.


Financial data and stock pages provided by
Fintel.io